Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of Itraconazole and Brepocitinib in Healthy Participants
NCT04090047Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brepocitinib in plaque psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and 2 more, sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measured concentration, Area under the plasma concentration-time curve from time zero to extrapolated infinite time and 1 more. Started Sep 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)systemic lupus erythematosus (SLE)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04090047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090047.